Project Grant R21AG093634
- This federal Project Grant award for $327,194 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to The Roskamp Institute, Inc., a biotechnology research organization based in Sarasota, Florida. The purpose of this 3-year award, with a performance period from September 1, 2024 to August 31, 2027, is to conduct research on delineating the therapeutic effect of PTEN inhibition for mitigating chronic microglia activation and the...
- This federal Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) provides $3,268,799.00 to The Roskamp Institute, Inc. to conduct research on the therapeutic effects of a novel blood-brain barrier-penetrable PPAR agonist compound for chronic outcomes following age-related repetitive mild traumatic brain injury. The award period spans from September 15, 2025 to September 14, 2029. The Roskamp Institute, a non-profit biotechnology...
- The Defense Health Agency awarded a $489,997 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to The Roskamp Institute, Inc. in Sarasota, Florida. The grant, awarded on September 1, 2024, will fund research to delineate the therapeutic effect of PTEN inhibition on mitigating chronic microglia activation and the chronic sequelae of repetitive mild traumatic brain injury (mTBI). The Roskamp Institute, a non-profit biotechnology research organization, has...
- The Defense Health Agency awarded a $749,905 Project Grant to The Roskamp Institute Inc. under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will fund research from September 2023 through September 2026 to investigate microglial NOX2/NLRP3 inflammasome activation and its role in driving tau pathology and cognitive impairments in chronic traumatic brain injury. Specifically, the Roskamp Institute will conduct basic, applied, and advanced biomedical...
- The U.S. Defense Health Agency awarded a $817,200 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to The Roskamp Institute, Inc. in Sarasota, Florida. The grant, awarded on September 1, 2024, will support a 3-year research project titled "Targeting APOE Bioenergetics for Reducing the Risk of Neurodegeneration After Chronic Traumatic Brain Injury." The research aims to investigate mitochondrial bioenergetics, tau protein pathology,...
- The Defense Health Agency awarded a $1,633,104 Project Grant to The Roskamp Institute, Inc. under the Military Medical Research and Development program (CFDA 12.420) to develop highly selective DYRK1A inhibitors as a novel therapeutic approach for traumatic brain injury. The grant, which runs from June 15, 2024 to June 14, 2028, supports the organization's research to understand the causes of and find cures for neuropsychiatric and neurodegenerative disorders. The Roskamp Institute, a non-profit...
- The Defense Health Agency awarded The Roskamp Institute, Inc. a $817,085 Project Grant under the Military Medical Research and Development program to conduct research on amnion cell secretome-mediated therapy for traumatic brain injury. The three-year award runs from June 1, 2023 to May 31, 2026 and will support The Roskamp Institute's investigation into potential therapies using amnion-derived cell treatments to address neuroinflammation and other vascular contributions to traumatic brain...
- This $6,214,900 Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program supports research on the role of genetic risk factors and immune response on neurovascular unit (NVU) function in post-traumatic brain injury (TBI) cognitive impairment. The primary awardee, the Scintillon Institute, a non-profit biomedical research organization in San Diego, California, will conduct this advanced scientific investigation over...
- This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, will fund research at the Augusta University Research Institute, Inc. (doing business as Georgia Health Sciences) to investigate the mechanisms linking traumatic brain injury (TBI) to subsequent neurodegeneration and dementia. The $1,975,262 award will support a 3-year study...
- This Project Grant award from the National Institute on Aging (Aging Research, CFDA 93.866) to Texas Tech University Health Sciences Center (TTUHSC) provides $192,737.00 to support research aimed at understanding the biological mechanisms linking traumatic brain injury (TBI) to the development of age-related diseases. The key focus is investigating how interactions between the biomarker UCHL1 and prostaglandins contribute to TBI-induced blood-brain barrier disruption, glycosaminoglycan...
This federal Project Grant award of $468,875.00 from the National Institute on Aging (CFDA 93.866 Aging Research program) supports research to investigate the effects of delayed microglial-specific PPARγ activation on ameliorating chronic neuroinflammation and cognitive dysfunction following repetitive mild traumatic brain injury (r-mTBI). The research, conducted by The Roskamp Institute, Inc. in Sarasota, FL, aims to clarify the role of microglial PPARγ signaling in regulating the persistent neuroinflammatory response and associated cognitive deficits observed in the chronic sequelae of r-mTBI. The grant has a performance period from Jan 1, 2026 to Dec 31, 2027. The project builds upon the institute's preclinical r-mTBI model and molecular profiling of microglia to optimize the therapeutic potential of targeting PPARγ for mitigating the long-term neurological consequences of repetitive head injuries.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $468.9k | 12/15/25 |